JPWO2021108918A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021108918A5 JPWO2021108918A5 JP2022534233A JP2022534233A JPWO2021108918A5 JP WO2021108918 A5 JPWO2021108918 A5 JP WO2021108918A5 JP 2022534233 A JP2022534233 A JP 2022534233A JP 2022534233 A JP2022534233 A JP 2022534233A JP WO2021108918 A5 JPWO2021108918 A5 JP WO2021108918A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lymphoma
- composition according
- cell
- acute lymphoblastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944876P | 2019-12-06 | 2019-12-06 | |
| US62/944,876 | 2019-12-06 | ||
| PCT/CA2020/051668 WO2021108918A1 (fr) | 2019-12-06 | 2020-12-04 | Traitement contre la leucémie myéloïde aiguë ou le syndrome myélodysplasique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505301A JP2023505301A (ja) | 2023-02-08 |
| JPWO2021108918A5 true JPWO2021108918A5 (fr) | 2023-12-11 |
Family
ID=76221282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534233A Pending JP2023505301A (ja) | 2019-12-06 | 2020-12-04 | 急性骨髄性白血病または骨髄異形成症候群に対する治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230010772A1 (fr) |
| EP (1) | EP4069246A4 (fr) |
| JP (1) | JP2023505301A (fr) |
| KR (1) | KR20220124177A (fr) |
| CN (1) | CN115397429A (fr) |
| AU (1) | AU2020396807A1 (fr) |
| BR (1) | BR112022011052A2 (fr) |
| CA (1) | CA3163796A1 (fr) |
| IL (1) | IL293623A (fr) |
| MX (1) | MX2022006910A (fr) |
| TW (1) | TW202134237A (fr) |
| WO (1) | WO2021108918A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| EP4337198A1 (fr) | 2021-05-11 | 2024-03-20 | Oric Pharmaceuticals, Inc. | Inhibiteurs de kinase de type polo 4 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010115279A1 (fr) * | 2009-04-06 | 2010-10-14 | University Health Network | Inhibiteurs de kinases et procédé de traitement du cancer avec ceux-ci |
| US8933070B2 (en) * | 2010-07-02 | 2015-01-13 | University Health Network | Methods of targeting PTEN mutant diseases and compositions therefor |
| WO2015051304A1 (fr) * | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions, biomarqueurs et leur utilisation dans le traitement du cancer |
| HUE043194T2 (hu) * | 2013-10-18 | 2019-08-28 | Univ Health Network | PLK-4 inhibitor sója és kristályformái |
| CA3074876A1 (fr) * | 2017-09-08 | 2019-03-14 | University Health Network | Polytherapies visant a inhiber la kinase 4 de type polo |
| US11612604B2 (en) * | 2017-12-06 | 2023-03-28 | Ludwig Institute For Cancer Research Ltd | Methods of treating cancer with PLK4 inhibitors |
-
2020
- 2020-12-04 MX MX2022006910A patent/MX2022006910A/es unknown
- 2020-12-04 JP JP2022534233A patent/JP2023505301A/ja active Pending
- 2020-12-04 BR BR112022011052A patent/BR112022011052A2/pt unknown
- 2020-12-04 AU AU2020396807A patent/AU2020396807A1/en active Pending
- 2020-12-04 CN CN202080095784.4A patent/CN115397429A/zh active Pending
- 2020-12-04 TW TW109142965A patent/TW202134237A/zh unknown
- 2020-12-04 CA CA3163796A patent/CA3163796A1/fr active Pending
- 2020-12-04 WO PCT/CA2020/051668 patent/WO2021108918A1/fr active Application Filing
- 2020-12-04 EP EP20895810.8A patent/EP4069246A4/fr active Pending
- 2020-12-04 IL IL293623A patent/IL293623A/en unknown
- 2020-12-04 US US17/782,632 patent/US20230010772A1/en active Pending
- 2020-12-04 KR KR1020227023046A patent/KR20220124177A/ko unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009090A5 (fr) | ||
| JP2012521435A5 (fr) | ||
| JP2023041862A5 (fr) | ||
| Prichard | Hypotensive action of pronethalol | |
| JP2021098728A5 (fr) | ||
| JP2006523216A5 (fr) | ||
| JP2015212268A5 (fr) | ||
| JP2019503365A5 (fr) | ||
| JP2009545601A5 (fr) | ||
| JP2020183416A5 (fr) | ||
| JP2005512995A5 (fr) | ||
| EP1976516A2 (fr) | Traitement de l'hépatite virale | |
| JP2008517991A5 (fr) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2005509662A5 (fr) | ||
| JP2014065696A5 (fr) | ||
| JP2002528502A5 (fr) | ||
| JP2006516571A5 (fr) | ||
| JP2023009229A5 (fr) | ||
| JPWO2021108918A5 (fr) | ||
| JP2007501806A5 (fr) | ||
| Donlon et al. | Successful suicides with thioridazine and mesoridazine: a result of probable cardiotoxicity | |
| JP6895688B2 (ja) | 血液がんの新規治療法及び新規治療剤 | |
| JP2020508351A5 (fr) | ||
| Weaver et al. | An amalgam tattoo causing local and systemic disease? |